The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
Abstract
We conducted a registry‐based study to determine prognostic indicators of 8‐year mortality and morbidity in young children with cystic fibrosis (CF). Patients ages 1–5 years from the 1990 U.S. Cystic Fibrosis Foundation (CFF) National Patient Registry served as the study cohort (N = 3,323). Registry data provided information on baseline characteristics in 1990, 8‐year mortality, and clinical outcomes in 1998. P. aeruginosa respiratory infection was found to be a major predictor of morbidity and mortality. The 8‐year risk of death was 2.6 times higher in patients who had respiratory cultures positive for P. aeruginosa in 1990 (95% confidence interval 1.6, 4.1) than in children without P. aeruginosa in their respiratory cultures. Culture‐positive patients in 1990 also had a significantly lower percent predicted forced expiratory volume in 1 sec (FEV 1) and weight percentile at follow‐up, and they had an increased risk of continued P. aeruginosa respiratory infection and hospitalization for acute respiratory exacerbation in 1998. Among the other predictors of increased morbidity and mortality were lower baseline weight percentiles and number of CF‐related hospitalizations during the baseline year. These findings confirm reports from previous smaller studies of outcomes among young children with CF, and highlight the potential to decrease the morbidity and mortality of young patients with CF through early intervention. Pediatr Pulmonol. 2002; 34:91–100. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Practical Statistics for Medical Research.
Walter, S. D., & Altman, D. G. (1992) · Biometrics · doi:10.2307/2532320 · Cited by 11,668
Practical Statistics for Medical Research
Altman, D. G. (1990) · doi:10.1201/9780429258589 · Cited by 10,668
Kupper, L. L., Hosmer, D. W., & Lemeshow, S. (1990) · Journal of the American Statistical Association · doi:10.2307/2290035 · Cited by 7,599
Modelling for Survival Data in Medical Research
(1995) · Technometrics · doi:10.1080/00401706.1995.10485920 · Cited by 2,145
Changes in the normal maximal expiratory flow-volume curve with growth and aging.
Knudson, R. J., Lebowitz, M. D., Holberg, C. J., & Burrows, B. A. (1983) · PubMed · doi:10.1164/arrd.1983.127.6.725 · Cited by 1,907
Modelling Survival Data in Medical Research
Collett, D. (1994) · Springer eBooks · doi:10.1007/978-1-4899-3115-3 · Cited by 1,065
Prediction of mortality in patients with cystic fibrosis
Kerem, E., Reisman, J., Corey, M., Canny, G. J., & Levison, H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204303261804 · Cited by 993
The changing epidemiology of cystic fibrosis
FitzSimmons, S. C. (1993) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)83478-x · Cited by 928
Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis
Nixon, G. M., Armstrong, D. S., Carzino, R., Carlin, J. B., Olinsky, A., Robertson, C. F., & Grimwood, K. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.112897 · Cited by 432
Cited by
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Gibson, R. L., Burns, J. L., & Ramsey, B. W. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200304-505so · Cited by 1,633
Self-citationCystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Flume, P. A., O'Sullivan, B. P., Robinson, K. A., Goss, C. H., Mogayzel, P. J., Willey-Courand, D. B., Bujan, J., Finder, J., Lester, M., Quittell, L., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-664oc · Cited by 1,024
The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections
Driscoll, J. A., Brody, S. L., & Kollef, M. H. (2007) · Drugs · doi:10.2165/00003495-200767030-00003 · Cited by 884
ECFS best practice guidelines: the 2018 revision
Castellani, C., Duff, A. J. A., Bell, S. C., Heijerman, H. G. M., Munck, A., Ratjen, F., Sermet-Gaudelus, I., Southern, K. W., Barben, J., Flume, P. A., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.02.006 · Cited by 765
Stallings, V. A., Stark, L. J., Robinson, K. A., Feranchak, A. P., & Quinton, H. (2008) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2008.02.020 · Cited by 732
Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Mogayzel, P. J., Naureckas, E. T., Robinson, K. A., Mueller, G., Hadjiliadis, D., Hoag, J. B., Lubsch, L., Hazle, L., Sabadosa, K., Marshall, B., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201207-1160oe · Cited by 615
European cystic fibrosis society standards of care: best practice guidelines
Smyth, A. R., Bell, S. C., Bojcin, S., Bryon, M., Duff, A., Flume, P., Kashirskaya, N., Munck, A., Ratjen, F., Schwarzenberg, S. J., et al. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.03.010 · Cited by 582
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium
Mesaros, N., Nordmann, P., Plésiat, P., Roussel-Delvallez, M., Van Eldere, J., Glupczynski, Y., Van Laethem, Y., Jacobs, F., Lebecque, P., Malfroot, A., et al. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01681.x · Cited by 585
Ratjen, F., Bell, S. C., Rowe, S. M., Goss, C. H., Quittner, A. L., & Bush, A. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.10 · Cited by 546
Rowe, S. M., Heltshe, S. L., Gonska, T., Donaldson, S. H., Borowitz, D., Gelfond, D., Sagel, S. D., Khan, U., Mayer-Hamblett, N., Van Dalfsen, J. M., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201404-0703oc · Cited by 492
Self-citationStandards of care for patients with cystic fibrosis: a European consensus
Kerem, E., Conway, S., Elborn, S., & Heijerman, H. (2005) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2004.12.002 · Cited by 477
Treatment of lung infection in patients with cystic fibrosis: Current and future strategies
Döring, G., Flume, P., Heijerman, H., & Elborn, J. S. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.10.004 · Cited by 474
Cystic Fibrosis Foundation Evidence-Based Guidelines for Management of Infants with Cystic Fibrosis
Borowitz, D., Robinson, K. A., Rosenfeld, M., Davis, S. D., Sabadosa, K. A., Spear, S. L., Michel, S. H., Parad, R. B., White, T. B., Farrell, P. M., et al. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.09.001 · Cited by 456
Self-citationExacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesis
Goss, C. H., & Burns, J. L. (2007) · Thorax · doi:10.1136/thx.2006.060889 · Cited by 445
Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis
Hauser, A. R., Jain, M., Bar-Meir, M., & McColley, S. A. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-10 · Cited by 411
Cystic fibrosis lung environment and Pseudomonas aeruginosa infection
Bhagirath, A. Y., Li, Y., Somayajula, D., Dadashi, M., Badr, S., & Duan, K. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0339-5 · Cited by 378
Madan, J. C., Koestler, D. C., Stanton, B. A., Davidson, L., Moulton, L. A., Housman, M. L., Moore, J. H., Guill, M. F., Morrison, H. G., Sogin, M. L., et al. (2012) · mBio · doi:10.1128/mbio.00251-12 · Cited by 356
MacKenzie, T., Gifford, A. H., Sabadosa, K. A., Quinton, H. B., Knapp, E. A., Goss, C. H., & Marshall, B. C. (2014) · Annals of Internal Medicine · doi:10.7326/m13-0636 · Cited by 355
The versatile use of exhaled volatile organic compounds in human health and disease
Boots, A. W., van Berkel, J. J. B. N., Dallinga, J. W., Smolinska, A., Wouters, E. F., & van Schooten, F. J. (2012) · Journal of Breath Research · doi:10.1088/1752-7155/6/2/027108 · Cited by 352
Filkins, L. M., Graber, J. A., Olson, D. G., Dolben, E. L., Lynd, L. R., Bhuju, S., & O'Toole, G. A. (2015) · Journal of Bacteriology · doi:10.1128/jb.00059-15 · Cited by 346
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Langton Hewer, S. C., & Smyth, A. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004197.pub4 · Cited by 324
Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis
Gibson, R. L., Emerson, J., McNamara, S., Burns, J. L., Rosenfeld, M., Yunker, A., Hamblett, N., Accurso, F., Dovey, M., Hiatt, P., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-855oc · Cited by 318
Self-citationKonstan, M. W., Flume, P. A., Kappler, M., Chiron, R., Higgins, M., Brockhaus, F., Zhang, J., Angyalosi, G., He, E., & Geller, D. E. (2011) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2010.10.003 · Cited by 314
Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology
Geller, D. E., Weers, J., & Heuerding, S. (2011) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2010.0855 · Cited by 308
Factors associated with FEV1decline in cystic fibrosis: analysis of the ECFS Patient Registry
Kerem, E., Viviani, L., Zolin, A., MacNeill, S., Hatziagorou, E., Ellemunter, H., Drevinek, P., Gulmans, V., Krivec, U., & Olesen, H. (2014) · European Respiratory Journal · doi:10.1183/09031936.00166412 · Cited by 296
Ratjen, F., Munck, A., Kho, P., Angyalosi, G., & for the ELITE Study Group (2010) · Thorax · doi:10.1136/thx.2009.121657 · Cited by 291
Managing Cystic Fibrosis: Strategies That Increase Life Expectancy and Improve Quality of Life
Cohen-Cymberknoh, M., Shoseyov, D., & Kerem, E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201009-1478ci · Cited by 287
Pseudomonas aeruginosa in Chronic Obstructive Pulmonary Disease
Murphy, T. F., Brauer, A. L., Eschberger, K., Lobbins, P., Grove, L., Cai, X., & Sethi, S. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1413oc · Cited by 280
Mogayzel, P. J., Naureckas, E. T., Robinson, K. A., Brady, C., Guill, M., Lahiri, T., Lubsch, L., Matsui, J., Oermann, C. M., Ratjen, F., et al. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201404-166oc · Cited by 269
Self-citationEnhanced Pseudomonas aeruginosa Biofilm Development Mediated by Human Neutrophils
Walker, T. S., Tomlin, K. L., Worthen, G. S., Poch, K. R., Lieber, J. G., Saavedra, M. T., Fessler, M. B., Malcolm, K. C., Vasil, M. L., & Nick, J. A. (2005) · Infection and Immunity · doi:10.1128/iai.73.6.3693-3701.2005 · Cited by 263
Araújo, D., Shteinberg, M., Aliberti, S., Goeminne, P. C., Hill, A. T., Fardon, T. C., Obradovic, D., Stone, G., Trautmann, M., Davis, A., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.01953-2017 · Cited by 259
Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis
Waters, V., Stanojevic, S., Atenafu, E. G., Lu, A., Yau, Y., Tullis, E., & Ratjen, F. (2012) · European Respiratory Journal · doi:10.1183/09031936.00159111 · Cited by 256
Cystic Fibrosis Lung Disease: An Overview
Turcios, N. L. (2020) · Respiratory Care · doi:10.4187/respcare.06697 · Cited by 217
Massive hemoptysis in cystic fibrosis
Flume, P. A., Yankaskas, J. R., Ebeling, M., Hulsey, T., & Clark, L. L. (2005) · Chest · doi:10.1378/chest.128.2.729 · Cited by 215
Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa
Millares, L., Ferrari, R., Gallego, M., Garcia-Nuñez, M., Pérez-Brocal, V., Espasa, M., Pomares, X., Monton, C., Moya, A., & Monsó, E. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2044-0 · Cited by 136
Lung function decline from adolescence to young adulthood in cystic fibrosis
VandenBranden, S. L., McMullen, A., Schechter, M. S., Pasta, D. J., Michaelis, R. L., Konstan, M. W., Wagener, J. S., Morgan, W. J., McColley, S. A., & for the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis (2012) · Pediatric Pulmonology · doi:10.1002/ppul.21526 · Cited by 128
Lechtzin, N., Mayer-Hamblett, N., West, N. E., Allgood, S., Wilhelm, E., Khan, U., Aitken, M. L., Ramsey, B. W., Boyle, M. P., Mogayzel, P. J., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201610-2172oc · Cited by 127
Self-citationHurley, M. N., Ariff, A. H. A., Bertenshaw, C., Bhatt, J., & Smyth, A. R. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.02.006 · Cited by 122
Adherence with tobramycin inhaled solution and health care utilization
Briesacher, B. A., Quittner, A. L., Saiman, L., Sacco, P., Fouayzi, H., & Quittell, L. M. (2011) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-11-5 · Cited by 95
Ramos, K. J., Quon, B. S., Heltshe, S. L., Mayer-Hamblett, N., Lease, E. D., Aitken, M. L., Weiss, N. S., & Goss, C. H. (2017) · Chest · doi:10.1016/j.chest.2017.01.019 · Cited by 95
Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis
Smith, S., Rowbotham, N. J., & Regan, K. H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001021.pub3 · Cited by 92
The impact of CFTR modulator therapies on CF airway microbiology
Rogers, G. B., Taylor, S. L., Hoffman, L. R., & Burr, L. D. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.07.008 · Cited by 52
Zhao, J., Cheng, W., He, X., & Liu, Y. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.09.010 · Cited by 39
Penesyan, A., Kumar, S. S., Kamath, K., Shathili, A. M., Venkatakrishnan, V., Krisp, C., Packer, N. H., Molloy, M. P., & Paulsen, I. T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138527 · Cited by 40
Barucha, A., Mauch, R. M., Duckstein, F., Zagoya, C., & Mainz, J. G. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2104249 · Cited by 6
Holzinger, J. M., Toelge, M., Werner, M., Ederer, K. U., Siegmund, H. I., Peterhoff, D., Blaas, S. H., Gisch, N., Brochhausen, C., Gessner, A., et al. (2023) · eLife · doi:10.7554/elife.86369 · Cited by 4
Metadata
- Authors
- Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., & Gibson, R. L.
- Venue
- Pediatric Pulmonology
- Publisher
- Wiley
- Published
- 2002-07
- Volume
- 34
- Issue
- 2
- Pages
- 91-100
- ISSN
- 1099-0496 (ISSN-L)
- 8755-6863
- OpenAlex
- W1971558827
- Cited by
- 1,007
- References
- 23
- FWCI
- 12.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.